CD44 mediates resistance to lenalidomide in MM (Bjorklund et al., 2014), and CD44-targeted T cells mediate potent anti-tumour effects against MM (Casucci et al., 2013). This evidence concerns the gene CD44 and Miyoshi myopathy.